Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. - Wikidata - wikimedia - TriplyDB

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

http://www.wikidata.org/entity/Q36080032

about

The use of lentinan for treating gastric cancer Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer.Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients.Recent developments in the treatment of gastric carcinoma.A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.Status of treatment for advanced gastric carcinoma.The role of chemotherapy in the current treatment of gastric cancer.Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas.Palliative chemotherapy for advanced gastric cancer.Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group.Docetaxel-associated epiphora.Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.Docetaxel in the treatment of gastric cancer.Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis.Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.Review of docetaxel in the treatment of gastric cancer.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Chemotherapy for metastatic disease: review from JCOG trials.Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.

P2860

Q24619416-478D6BB9-46BE-4E7D-A64D-17D98F4D826F Q24635111-1D12F229-97BE-4F18-ADE2-8EEB01104FE9 Q24810562-B2750AA7-D912-434E-A020-05874EDDC49C Q28350903-9635322D-3DEA-48B7-9E40-130466A6D434 Q33180637-46135855-EEC9-4460-9080-86523929CB29 Q33341264-E70AF10F-4799-4BA1-BD07-93BC1D80989A Q33349888-F78353EC-E935-42EA-999E-E6B8C033CEF1 Q33385867-8182ED78-E3E3-48CF-900F-863ADEB12359 Q33403949-72B18651-D9F1-4196-92F2-79DD206DC3EF Q33415440-125232C7-F83B-41EC-ABAD-93597D4FFA20 Q33594906-2FD96F05-3875-4A65-8397-E53F3B98C343 Q34159161-DB22BBD1-B73F-4ABE-935A-D99A5623B2DF Q34585843-5BA9BD8B-A0E1-4A7A-88B7-1B1E2367DAC7 Q34590788-2AD0C3D5-8FEF-4BED-BB83-5A55701CD342 Q34620042-6BEF0274-4B0A-40A8-B339-8CC0AC7DB946 Q35095365-3D0CC471-9049-4E72-A379-B9DFA65B9D5C Q35139161-8240CEF2-0C9D-4F4E-8B3D-752C35182006 Q35181089-CB3CA829-CA86-4AFD-ADD2-6841058FE49C Q35936039-F9AC3D1F-07D9-4882-A8FF-A1F3D5872F7D Q36295002-F021CF4B-8A2C-4B8F-B976-0626EE327500 Q36376439-3FF3D1A4-79A4-446A-9858-8A64C5AC81D4 Q36396339-BBE3742E-71E5-4B7D-9CED-CB74F0E5A97E Q36459767-DD825826-FFC7-408F-A8E7-6EC7BFF5616C Q36484970-35070CEC-2907-469D-9D20-28DC17D70712 Q36548725-26EA31F1-6F53-413C-A552-0003D32A26E4 Q36611262-4ECF7A9D-A475-4761-9C90-D193B8C379A3 Q36614148-F965FEA5-523A-4F31-9A14-3FB55BFF9BD9 Q36614394-2D9373BC-6E89-4686-87D2-08A6CA95EA22 Q36614734-ABB90D0F-3800-415A-80A2-097F6ACCA1DC Q36615597-151C36F7-0A38-43D6-A572-9C9E0E951A8A Q36616308-67A4438D-10D0-4AD9-AFE2-D8E7520E656B Q36616503-67DD6891-4A2D-47D5-8578-F684B3D9EA92 Q36625990-8801C554-446D-4FDB-8E96-80C6162548CD Q36674440-F96FCF96-5961-4341-8806-356B4A924332 Q36795339-1770606A-5F76-41A9-84DD-8F3053F6E022 Q36853997-BC763F71-0C14-43D6-B21D-0A58AE4FFA1F Q37052880-C132DD7E-4178-4078-A724-7D1D13183621 Q37077239-6DE95785-7F89-42DF-8392-67CCCA873E9E Q37191094-C3548375-C66E-49AD-95D5-8CC76FBA0B06 Q37214866-783AAA45-9131-4FC4-9DAD-A9290263867A

P2860

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

http://www.wikidata.org/entity/Q36080032

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年論文

@yue

1994年論文

@zh-hant

1994年論文

@zh-hk

1994年論文

@zh-mo

1994年論文

@zh-tw

1994年论文

@wuu

1994年论文

@zh

1994年论文

@zh-cn

name

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@ast

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@en

type

label

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@ast

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@en

prefLabel

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@ast

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@en

P1433

Q36080032-7FACBE4C-A40E-44AE-B05E-FF2C22920DEC

P1476

Q36080032-8AD59085-834B-4C4B-82E3-8E4ECF2420BF

P2093

Q36080032-15B543ED-D918-47F8-8E16-22448E4BD255

Q36080032-5BE661A7-CE93-491C-BF5D-CE95F264BB76

Q36080032-80C4FC0E-5319-4D51-BF82-4410A0B8DD82

Q36080032-9FF33BD8-2B64-4785-A95F-1AEECA219C93

Q36080032-B5E527D3-365A-4A9B-99D2-3DA8BE199E33

Q36080032-BA3E4EB0-33DB-4916-9118-D87E7596CD81

Q36080032-BE8DF10A-DAD5-4B68-8F81-972C762DDD51

Q36080032-C4D01419-721F-42CD-B434-DE2142C7920D

Q36080032-C859C121-8DD9-46AF-A536-A4B65E79EA1E

Q36080032-F3D525B1-EB3F-43AE-8AF6-28B3A21D9F55

P2860

Q36080032-1D4B0B91-AEF4-4309-90EC-08AA45B798CF

Q36080032-619BDD72-22AA-4064-90AA-853ABB4FA830

Q36080032-8D8F5330-2A49-4813-9354-687B89FA204B

Q36080032-B1A69CA3-F7E9-4A57-8FB0-198619680B5A

P2888

Q36080032-4F2442EF-6C85-4276-A4C2-E032B34ADA7C

P304

Q36080032-9CD05B6C-6202-480B-8643-DE3F238E4AD6

P31

Q36080032-DA0BA0E3-1E10-4EFF-B403-C3D211D606F8

P356

Q36080032-B34D23AF-AD22-44D0-AADB-9CB54DA0E340

P407

Q36080032-45587750-6522-4E52-B5BA-5B3EAEE17045

P433

Q36080032-C52E6F03-3FBC-4F03-BF78-BAE30C7A26CC

P478

Q36080032-9FBF7640-9C7B-4E9D-8CC0-F770D6B7F16F

P577

Q36080032-DCA36C49-CDB6-4708-9FEC-2BAF7234BE0A

P5875

Q36080032-5DFE59CD-877E-4F61-98C5-BEE3F187012B

P698

Q36080032-38C27BC1-049C-4A17-91EB-40445E35CD67

P921

Q36080032-04E2C9E7-56DF-4D69-8E00-B2A0783636E2

P932

Q36080032-C79CF32E-A9E7-4464-9947-0A7229CD7713

P356

P1433

British Journal of Cancer

P1476

Docetaxel (Taxotere) in advanc ...... C Early Clinical Trials Group.

@en

P2093

A Sulkes

http://www.w3.org/2001/XMLSchema#string

C Sessa

http://www.w3.org/2001/XMLSchema#string

H Franklin

http://www.w3.org/2001/XMLSchema#string

J B Vermorken

http://www.w3.org/2001/XMLSchema#string

J Smyth

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

J Wanders

http://www.w3.org/2001/XMLSchema#string

L Y Dirix

http://www.w3.org/2001/XMLSchema#string

N LeBail

http://www.w3.org/2001/XMLSchema#string

S Kaye

http://www.w3.org/2001/XMLSchema#string

P2860

Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.

Chemotherapy of gastric cancer: a review.

Relationships between the structure of taxol analogues and their antimitotic activity.

P2888

P304

380-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1994.310

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

1994-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15285661

http://www.w3.org/2001/XMLSchema#string

P698

7914428

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2033505

http://www.w3.org/2001/XMLSchema#string